Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083938 | PMC |
| http://dx.doi.org/10.4084/MJHID.2022.042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer.
Technol Cancer Res Treat
October 2024
Department of Clinical Pathology-Hematology and AinShams Medical Research Institute (MASRI), Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Resistance to Trastuzumab is a significant challenge in the management of HER2-positive Metastatic Breast cancer (HER2-MBC), and a better understanding of the molecular causes of resistance is required to develop more effective treatment plans. While elevated plasma levels of miR-200 and FOXP3 have been linked to breast cancer progression and treatment response, no clinical studies have confirmed these results. The study involved 40 patients with HER2-positive metastatic breast cancer (HER2-MBC).
View Article and Find Full Text PDFNRN1 genetic variability and methylation changes as biomarkers for cognitive remediation therapy response in schizophrenia.
Prog Neuropsychopharmacol Biol Psychiatry
October 2024
FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain. Electronic address:
Cognitive remediation therapy (CRT) demonstrates potential in enhancing cognitive function in schizophrenia (SZ), though the identification of molecular biomarkers remains challenging. The Neuritin-1 gene (NRN1) emerges as a promising candidate gene due to its association with SZ, cognitive performance and response to neurotherapeutic treatments. We aimed to investigate whether NRN1 genetic variability and methylation changes following CRT are related to cognitive improvements.
View Article and Find Full Text PDFPotential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review.
Transl Lung Cancer Res
May 2024
Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
Article Synopsis
- Neoadjuvant chemoimmunotherapy (NACI) is the recommended treatment for patients with operable non-small cell lung cancer (NSCLC), but finding a reliable predictor for achieving a pathological complete response (pCR) remains a challenge.* -
- A review of 50 relevant studies published between 2018 and 2022 highlighted various potential predictors for pCR, including imaging techniques like F-FDG-PET, tumor microenvironment factors, and clinical markers such as neutrophil-to-lymphocyte ratio (NLR) and smoking history.* -
- Notably, a full metabolic response on PET scans showed a 71.4% positive predictive value for pCR, while specific patterns in tumor
Macro CD5L deteriorates CD8T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.
Nat Commun
January 2024
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Article Synopsis
- Intratumoral immune status plays a crucial role in how patients with intrahepatic cholangiocarcinoma respond to therapy, especially with a combination of gemcitabine, oxaliplatin, lenvatinib, and anti-PD1 antibody.
- High levels of certain CD8 T-cell markers (GZMB and proliferating CD8) and low levels of Macro CD5L predict better therapeutic responses, while shifts in T-cell markers indicate varying response levels.
- The study also suggests that using anti-CTLA4 antibody can counteract therapy resistance caused by immune exhaustion, paving the way for more effective cancer treatments based on immune profiling.
Rapid predictive dosimetry for Second Strike prescription based on whole body radioiodine kinetics in differentiated thyroid cancer.
Asia Ocean J Nucl Med Biol
January 2024
Department of Nuclear Medicine, The Royal Melbourne Hospital, Victoria, Australia.
Article Synopsis
- The study focuses on improving post-therapy dosimetry in systemic radionuclide therapy for thyroid cancer by using a rapid predictive dosimetry method instead of traditional multi-time point analysis.
- This method utilizes a patient's specific time-activity curve for accurate dose calculations based on their exposure rates, which streamlines the prescription process for follow-up treatment.
- A Predictive Calculator spreadsheet has been developed to make this predictive dosimetry accessible and efficient for use in clinical settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!